<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019331</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065656</org_study_id>
    <secondary_id>NCI-97-C-0141F</secondary_id>
    <secondary_id>NCI-T96-0078</secondary_id>
    <nct_id>NCT00019331</nct_id>
    <nct_alias>NCT00001581</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors</brief_title>
  <official_title>Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill
      tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more
      effective treatment for solid tumors.

      PURPOSE: Phase II trial to study the effectiveness of vaccine therapy plus interleukin-2
      and/or sargramostim in treating adults who have metastatic solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether endogenous cellular immunity to a tumor-specific mutated ras protein
           is present in cancer patients.

        -  Determine whether vaccination with synthetic peptides corresponding to the tumor's ras
           mutation with DetoxPC adjuvant, interleukin-2 (IL-2), and/or sargramostim (GM-CSF) can
           induce or boost a patient's cellular immunity to that particular mutation.

        -  Determine the type and characteristics of the cellular immune response generated.

        -  Determine the tolerance to and toxicity spectrum of such peptides given with DetoxPC
           adjuvant along with IL-2 and/or GM-CSF.

        -  Correlate immune response with tumor response in patients treated with these regimens.

      OUTLINE: Patients are assigned to one of three treatment groups.

        -  Group I (closed to accrual 6/4/01): Patients receive tumor-specific ras peptide vaccine
           with DetoxPC subcutaneously (SC) once every 5 weeks for 3 courses. Beginning 4 days
           after vaccination, patients receive interleukin-2 (IL-2) SC 5 days a week for 2 weeks.

        -  Group II (closed to accrual 6/4/01): Patients receive sargramostim (GM-CSF) SC daily
           beginning 1 day prior to the vaccination and continuing for 4 days. Patients receive the
           vaccination as in group I immediately followed by GM-CSF on day 2. Patients are
           vaccinated once every 4 weeks for 3 courses.

        -  Group III: Patients receive the vaccination and IL-2 as in group I and GM-CSF as in
           group II.

      In all groups, patients receive up to 15 vaccinations in the absence of disease progression.

      Patients are followed every 2 months.

      PROJECTED ACCRUAL: A maximum of 60 patients (20 per treatment group) will be accrued for this
      study within 2-4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ras peptide cancer vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DetoxPC</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed solid tumors potentially expressing mutant ras, including
             colon, lung, pancreas, thyroid, endometrial, head and neck, testicular,
             hepatocellular, and melanoma

          -  Ras mutations must be one of the following point mutations at codon 12:

               -  Glycine to cysteine

               -  Glycine to aspartic acid

               -  Glycine to valine

          -  Metastatic disease for which no known chemotherapy or radiotherapy would increase
             survival

          -  Tumor tissue must be available for determination of ras mutation

          -  No prior CNS metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-1

        Life expectancy:

          -  More than 3 months

        Hematopoietic:

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

          -  SGOT/SGPT no greater than 4 times normal

          -  No hepatitis B or C infection

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular:

          -  No active ischemic heart disease (New York Heart Association class III or IV)

          -  No myocardial infarction within the past 6 months

          -  No history of congestive heart failure, ventricular arrhythmias, or other arrhythmias
             requiring therapy

        Immunologic:

          -  No prior allergy to eggs

          -  No prior autoimmune disease, including the following:

               -  Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia

               -  Systemic lupus erythematosus, Sjogren's syndrome, or scleroderma

               -  Myasthenia gravis

               -  Goodpasture syndrome

               -  Addison's disease, Hashimoto's thyroiditis, or active Graves' disease

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No other active malignancy except curatively treated carcinoma in situ of the cervix
             or basal cell skin cancer

          -  No active infection requiring antibiotics

          -  No medical condition that would preclude study

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy and recovered

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior chemotherapy and recovered

        Endocrine therapy:

          -  At least 4 weeks since prior steroids and recovered

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy and recovered

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry L. Gause, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>stage IV papillary thyroid cancer</keyword>
  <keyword>stage IV follicular thyroid cancer</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <keyword>anaplastic thyroid cancer</keyword>
  <keyword>recurrent thyroid cancer</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>insular thyroid cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

